Clinical trials: Obesity and Overweight
Obesity, Morbid Obesity
Effects of a Novel Dietary Intervention on Body Composition After Laparoscopic Gastric Bypass Surgery
We propose to compare the standard of care with the use of a novel medical food in 6 bariatric surgery patients by measuring outcomes of body composition, quality of life, hair loss, muscle strength, resting energy expenditure…
- Trial name
- NCT01041261
- Testing
- BariatrX Essentials 360 Treatment
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- MetaProteomics LLC
Obesity
Endostapler Sleeve Gastrectomy Study
The goal of this prospective, post-market study is to measure AEON™ Endostapler performance for laparoscopic sleeve gastrectomy surgery versus the Endo GIA™ Reloads with Tri-Staple™ Technology from Medtronic.
- Trial name
- NCT04617574
- Testing
- AEON Endostapler, Endo GIA Reloads with Tri-Staple Technology
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Lexington Medical Inc.
Overweight,Obesity
Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese Participants
ZT006 is an oral, long-acting glucagon-like peptide-1. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT006 in healthy, overweight and obese participants.
- Trial name
- NCT07307638
- Testing
- ZT006
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Obesity, Obese
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
- Conditions
- Obesity, Obese, Overweight or Obesity
- Trial name
- NCT05616013
- Testing
- Bimagrumab, Semaglutide
- Where
- 26 sites in United States, Australia and 1 more
- Volunteers
- 507 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Effects of the GOLO for Life System Diet With and Without GOLO Release Supplement on Glycemic Control and Insulin Resistance
This randomized, double-blind placebo-controlled study is intended to observe the short-term effects of the GFL System Diet with Release supplement versus GFL System Diet with placebo on glycemic metabolism and insulin resistance…
- Trial name
- NCT04082390
- Testing
- RELEASE
- Volunteers
- 36 people
- Sponsor
- Golo
Obesity
A Phase 1b Study to Evaluate the Safety of XEN-101
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
- Trial name
- NCT06417697
- Testing
- XEN-101
- Where
- Australia
- Volunteers
- 33 people
- Sponsor
- Xeno Biosciences
Prader-Willi Syndrome
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
The objective of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in participants with Prader-Willi Syndrome.
- Trial name
- NCT03458416
- Testing
- Cannabidiol Oral Solution
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Obesity, Non-morbid
METHOD (Minimally Invasive, Endoscopically-delivered, Tolerable by Human Individuals, Non-morbid Obesity Device) Study
This will be an open label, single-center, feasibility study comprised of two sequential cohorts( cohort 1: 2 participants; cohort 2: 8 participants).
- Trial name
- SENSATE (NCT00753350)
- Testing
- Sensate™ anchored gastric device
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Sensate LLC
Obesity
Endoscopic Bariatric Stapling Pilot Study
This study is a prospective single-arm, multicenter study to evaluate the safety and effectiveness of the TOGA® Procedure for the treatment of morbid obesity.
- Trial name
- TOGA® (NCT01067625)
- Testing
- TOGA® System
- Where
- 2 sites in Belgium, Italy
- Volunteers
- 200 people
- Sponsor
- Satiety, Inc.
Overweight, Obesity
A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity
The main objectives of this trial are to investigate safety, tolerability of alternative dose titration strategies and pharmacokinetics (PK) of BI 3034701 in participants with overweight / obesity and at least one weight related…
- Trial name
- NCT07754474
- Testing
- BI 3034701
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Overweight
Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women
Before and after study in obese women 25-35 years old, BMI 30-35, taking Strath® Kräuterhefe Original (liquid), Herbal Yeast Food Supplement for three weeks.
- Trial name
- NCT03223987
- Testing
- Strath® Kräuterhefe Original (liquid)
- Where
- Switzerland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bio-Strath AG
Obesity, Roux-en-Y Gastric Bypass
A Registry of Laparoscopic Bariatric Surgery Using Stapling Devices: Observation of Safety and Clinical Efficacy
The purpose of this observational registry is to evaluate the safety and the clinical efficacy of laparoscopic bariatric surgery using stapling devices (easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg…
- Conditions
- Obesity, Roux-en-Y Gastric Bypass, Gastrostomy, Nissen Sleeve
- Trial name
- STAP-JOLI (NCT04808206)
- Testing
- easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
- Where
- 3 sites in Belgium
- Volunteers
- 150 people
- Sponsor
- Duomed
Psoriatic Arthritis, Overweight or Obesity
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related…
- Trial name
- NCT06864026
- Testing
- Tirzepatide
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects
This study examines whether a gradual increase of dose improves the gastrointestinal tolerability (nausea and vomiting) of PF05212389
- Trial name
- NCT01472848
- Sponsor
- Pfizer
Obesity
Signature Diagnostic of Non-alcoholic Steatohepatitis (NASH) by Infrared Light Spectroscopy
Evaluation of the diagnostic performance of an algorithm developed to detect metabolic profiles specific of non-alcoholic steatohepatitis NASH and based on the reading of a blood sample's infrared spectra
- Trial name
- SIGNALS (NCT03978247)
- Testing
- NASHMIR
- Where
- Belgium
- Volunteers
- 382 people
- Sponsor
- Diafir
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Obesity or Overweight, Type 2 Diabetes
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or…
- Trial name
- ZUPREME-4 (NCT07843485)
- Testing
- Petrelintide
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
Type II Diabetes Mellitus
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities.
- Trial name
- NCT07282743
- Testing
- GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3
- Where
- 21 sites in United States, India
- Volunteers
- 285 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Weight Gain
Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study. Approximately 78 subjects (39 per treatment group) will be randomized into this 16 week study.
- Trial name
- NCT00428168
- Testing
- Betahistine
- Where
- 10 sites in Canada, Israel
- Volunteers
- 36 people
- Sponsor
- OBEcure Ltd.
Obesity or Overweight
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
The study is investigating weight loss and treatment patterns associated with the use of Saxenda® in adult patients. The aim of the study is to assess the weight loss associated with Saxenda® in patients with obesity or…
- Trial name
- NCT05153590
- Testing
- Saxenda®
- Where
- Denmark
- Volunteers
- 269 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.